Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study
Authors:
- Judy GnarpeJGJudy Gnarpe
- Eva LonnELEva Lonn
- HåkAn GnarpeHGHåkAn Gnarpe
- Gunnar OlssonGOGunnar Olsson
- Qilong YiQYQilong Yi
- Vladimir DzavikVDVladimir Dzavik
- Matthew McQueenMMMatthew McQueen
- Salim YusufSYSalim Yusuf
- 21 January 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 107 (2) , 251-257
Abstract
Background— Limited prospective epidemiological data are available on the relation between exposure to Chlamydia pneumoniae , Helicobacter pylori , cytomegalovirus (CMV), and hepatitis A virus (HAV), individually or as a total pathogen score, and human cardiovascular (CV) disease. Methods and Results— We analyzed enrollment sera from 3168 Canadian patients in the Heart Outcomes Prevention Evaluation (HOPE) study for antibodies to C pneumoniae , H pylori , CMV, and HAV and measured the relation between serostatus and 494 adjudicated trial outcomes of myocardial infarction, stroke, or CV death over 4.5 years of follow-up. CV events were associated with CMV serostatus (covariate-adjusted hazard ratio [HR], 1.24; 95% CI, 1.01, 1.53). Neither C pneumoniae IgG (adjusted HR, 0.87; 95% CI, 0.68, 1.10), C pneumonia IgA (adjusted HR, 1.10; 95% CI, 0.90, 1.34), H pylori IgG (HR, 0.99; 95% CI, 0.82, 1.19), nor HAV IgG (HR, 1.01; 95% CI, 0.83, 1.24) predicted CV events. Total pathogen score was associated with CV events (adjusted HR for 4 versus 1 or 0=1.41; 95% CI, 1.02, 1.96). Conclusions— Exposure to CMV but not to C pneumoniae , H pylori , or HAV was associated with a slight excess risk of subsequent myocardial infarction, stroke, or CV death in HOPE study patients, and total pathogen score based on these infections predicted a small increased hazard of CV events.Keywords
This publication has 18 references indexed in Scilit:
- The Possible Role of Hepatitis A Virus in the Pathogenesis of AtherosclerosisThe Journal of Infectious Diseases, 2000
- Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis Commentary: Adjustment for potential confounders may have been taken too farBMJ, 2000
- Rationale and Design of a Secondary Prevention Trial of Antibiotic Use in Patients after Myocardial Infarction: The WIZARD (Weekly Intervention with Zithromax [Azithromycin] for Atherosclerosis and Its Related Disorders) TrialThe Journal of Infectious Diseases, 2000
- Description and Status of the Azithromycin and Coronary Events Study (ACES)The Journal of Infectious Diseases, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Seroprevalence of Antibodies to Chlamydia pneumoniae in Elderly People: A Two-decade Longitudinal and Cohort Difference StudyScandinavian Journal of Infectious Diseases, 2000
- Association between Prior Cytomegalovirus Infection and the Risk of Restenosis after Coronary AtherectomyNew England Journal of Medicine, 1996
- Demonstration of Chlamydia pneumoniae in Atherosclerotic Lesions of Coronary ArteriesThe Journal of Infectious Diseases, 1993
- SEROLOGICAL EVIDENCE OF AN ASSOCIATION OF A NOVEL CHLAMYDIA, TWAR, WITH CHRONIC CORONARY HEART DISEASE AND ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1988
- Virus-induced atherosclerosis.Journal of Experimental Medicine, 1978